Study Comparing Olanzapine With Haloperidol for the Relief of Nausea and Vomiting in Patients With Advanced Cancer

Alberta Health services

Status and phase

Terminated

Phase 3

Conditions

Nausea

Neoplasms

Treatments

Drug: Olanzapine

Drug: Haldol

Study type

Interventional

Funder types

Other

Identifiers

NCT00124930

MCT 71119

18731

ISRCTN58624349

Details and patient eligibility

About

The purpose of this study is to compare the efficacy and safety of Haldol (haloperidol) and olanzapine in the control of chronic nausea with advanced cancer patients who have failed first line antiemetic therapy.

Full description

The purpose of this study is to compare the efficacy and safety of haloperidol and olanzapine in the control of chronic nausea with advanced cancer patients who have failed first line antiemetic therapy.

Enrollment

80 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

>18 years of age
Significant nausea/vomiting
Failed maxeran and domperidone
Underlying treatment of causes has failed
Adequate cognitive function
Communicates well

Exclusion criteria

Partial/complete bowel obstruction
Currently taking Haldol or olanzapine
Has drug induced extrapyramidal symptoms
Parkinson's disease
Undergoing chemotherapy or radiotherapy (RT) to brain, abdomen, stomach or esophagus